Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1392926 | 0.83 | MEN1 (0.38) | DUTALDH1A1KMT2AMAPTPKM | |
| SCHEMBL16769196 | 0.83 | DUT (0.37) | DUTALDH1A1KMT2ALMNAHTT | |
| SCHEMBL24579070 | 0.81 | DUT (0.36) | DUT | |
| SCHEMBL25259763 | 0.81 | DUT (0.36) | DUTALDH1A1KMT2AHSD17B10HPGD | |
| SCHEMBL16784470 | 0.81 | DUT (0.36) | DUT | |
| SCHEMBL26059803 | 0.79 | DUT (0.35) | DUT | |
| SCHEMBL19992131 | 0.78 | DUT (0.36) | DUT | |
| SCHEMBL11931264 | 0.78 | DUT (0.34) | DUT | |
| SCHEMBL24420592 | 0.77 | L3MBTL1 (0.57) | DUTHSD17B10 | |
| SCHEMBL24197369 | 0.77 | DUT (0.33) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4522616-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-115873000-B | Isoquinolinones and quinazolinones compounds, and composition and application thereof | 中山医诺维申新药研发有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119403801-A | LRRK2 inhibitors | 因特来治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-116854680-A | Isoxazole-heterocycle derivatives, pharmaceutical composition and application | 上海赛默罗生物科技有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-115873000-A | Isoquinolone and quinazolinone compounds, and composition and application thereof | 中山医诺维申新药研发有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2023044171-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2022011211-A1 | DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-9849109-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2606031-B1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9000025-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2606031-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, SERPINE1 | DUT 3999/4885ALDH1A1 4786/4885KMT2A 3249/4885 |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, SERPINE1 | DUT 3999/4885ALDH1A1 4786/4885KMT2A 3249/4885 |
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | DUT 3831/4885ALDH1A1 2142/4885KMT2A 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.